Patient-controlled Analgesia Pumps Market Size
|2021 - 2029
|Base Year For Estimation
|Forecast Data Period
|2024 - 2029
|Fastest Growing Market
*Disclaimer: Major Players sorted in no particular order
Need a report that reflects how COVID-19 has impacted this market and its growth?
Patient-controlled Analgesia Pumps Market Analysis
The patient-controlled analgesia (PCA) pump market is expected to register a CAGR of 5.2% over the forecast period.
The healthcare system witnessed enormous challenges as a result of the COVID-19 pandemic. During the first phase of COVID-19, the expansion of the patient-controlled analgesia pump market was significantly constrained for several uncertain reasons. However, there is an increasing occurrence of chronic pain in patients who recovered from COVID-19 infection. For instance, as per the Current Pain and Headache Reports in March 2022, the vaccination for COVID-19 in the United States may be reducing the number of new SARS-CoV-2 cases, but the population of those suffering from the virus's long-term symptoms is growing. One of these long-term side effects includes chronic pain syndromes. Hence, to manage the chronic pain of COVID-19-recovered patients, there is a need for patient-controlled analgesia pumps, which help the patient control their pain. This is expected to positively impact the market over the forecast period.
The major factors attributing to the market's growth are the increasing prevalence of chronic pain diseases such as arthritis, cancer, and fibromyalgia, along with the technological advancements with enhanced safety features in the PCA pumps. Fibromyalgia is a condition that causes pain all over the body, also called widespread pain. The increase in the prevalence of fibromyalgia helps the growth of the patient-controlled analgesia pump market. For instance, according to the updated data from CDC in May 2022, about 4 million US citizens, or 2% of all adults, suffer from fibromyalgia. Although there is no known cause for fibromyalgia, it is treatable and manageable with various pain management methods, one of which is a patient-controlled analgesia pump. Hence a significant burden of chronic pain diseases like fibromyalgia increases the usage of patient-controlled analgesia pumps and drives the market's growth over the study period.
The recent product launches and approvals by the regulatory authorities focusing on patient-controlled analgesia pumps are expected to aid in the market's growth, as these approvals will increase product availability and competition in the market. For instance, in April 2021, Becton, Dickinson, and Company submitted a 510(k) premarket notification to the US FDA for the BD Alaris System. The system allows clinicians to deliver pain medications and fluids through a single integrated platform that includes large-volume pumps and syringe pumps for adult, pediatric and neonatal patients. Thus, the large population affected by chronic pain-causing diseases and the increasing product approvals are expected to add to the growth of the studied market over the forecast period. However, the lack of awareness resulting in patient medication errors and the stringent regulatory framework and associated product recalls are likely to slow down the market growth over the forecast period.
Patient-controlled Analgesia Pumps Market Trends
This section covers the major market trends shaping the Patient-controlled Analgesia Pumps Market according to our research experts:
Oncology is Expected to Hold the Major Market Share in the Market Over the Forecast Period
The oncology segment is expected to account for a significant market share during the forecast period due to the widespread prevalence of cancers worldwide. Cancer pain is often described as a throbbing, pressing, burning, or tingling sensation that can be managed through PCA pumps, and hence, the demand for PCA pumps is expected to increase with the rising burden of cancer. For Instance, according to the Canadian Cancer Statistics 2021, in Canada, 229,200 new cancer cases were detected in 2021. Similarly, as per the report published by the CMAJ Group in 2022, an estimated 233,900 people in Canada will be diagnosed with cancer in 2022. Thus, the increase in new cases of cancer in the region will increase the demand for pain management, which can be achieved using patient-controlled analgesia pumps. Therefore, growth in the market is expected. Highly potent opioid drugs, such as hydro morphine, morphine, and fentanyl through patient-controlled analgesia (PCA) infusion, are prescribed by physicians to treat unbearable pain. The rising adoption of PCA pumps in such conditions to improve the quality of life is expected to promote the segment's growth.
Similarly, the increase in patient satisfaction with cancer pain management with the use of patient-controlled analgesics plays a significant role in market growth. For instance, as per an article published by the JNCCN Journal in August 2021, the programmable patient-controlled analgesia (PCA) pump allows patients to control pain on demand and also promptly responds to the patient's changing needs, and it reduces analgesic delay. The PCA significantly reduced successful titration and average pain score for persistent severe cancer pain. Thus, the preference for PCA pumps for cancer pain management is expected to boost the growth of the segment.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
North America is expected to dominate the overall PCA pumps market owing to the rise in the number of cases of cancer, accidental injuries, and other ailments related to pain and the rise in research funding on chronic pain.
The high prevalence of cancer cases in the North American region is expected to add to the market's growth. For instance, as per the ACS 2021 & 2022 report, in the United States, 1,898,160 new cancer cases were estimated in 2021, which is going to rise in 2022 to 1,918,030 new cancer cases. Excluding non-melanoma skin cancer, 42% of cancer cases in the United States that are newly diagnosed, or around 805,600 cases in 2022, may be preventable. Thus, the rising prevalence of cancer cases in the region is likely to boost the market's growth in the region over the forecast period.
Furthermore, the rise in research funding on chronic pain is also expected to propel the market's growth in the region. For instance, as per NIH 2022, the research funding for chronic pain in the United States for 2021, 2022, and 2023 is estimated at USD 725 million, USD 750 million, and USD 862 million, respectively. In addition, the partnerships and acquisitions among the key market players in the region are also adding to the market's growth. For instance, in January 2022, California-based ICU Medical acquired the Smiths Medical Division, which includes syringe and ambulatory infusion devices, vascular access, and vital care products from Smiths Group Plc. Such activities are likely to expand the portfolio of companies, which are expected to witness significant growth over the forecast period in the North American region.
Patient-controlled Analgesia Pumps Industry Overview
The PCA pumps market is moderately competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some prominent players are developing safe and trouble-free systems with novel technologies, while others are distributing them. Some of the companies that are currently dominating the market are ICU Medical Inc. (Smiths Medical), BD (Becton, Dickinson and Company), Fresenius SE & Co. KGaA, B. Braun SE, and Baxter.
Patient-controlled Analgesia Pumps Market Leaders
B. Braun SE
BD (Becton Dickinson, and Company)
Fresenius SE & Co. KGaA
ICU Medical, Inc (Smiths Medical)
*Disclaimer: Major Players sorted in no particular order
Patient-controlled Analgesia Pumps Market News
- August 2022: The US FDA issued 510(k) clearance for Baxter's new Novum IQ syringe infusion pump (SYR) with Dose IQ Safety Software. Baxter is one of the global leaders in infusion therapy and pain management, and the Novum IQ pump is a significant addition to its product portfolio.
- March 2022: Shanghai MicroPort Lifesciences Co. Ltd received marketing approval from NMPA, China, for its independently-developed AutoEx Chemotherapy Infusion Pump (AutoEx). It is the first approved product in the company's intelligent oncology pain solutions portfolio.
Patient-controlled Analgesia Pumps Market Report - Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Technological Advancements with Enhanced Safety Features
4.2.2 Rising Prevalence of Chronic Pain Diseases like Cancer and Arthritis
4.3 Market Restraints
4.3.1 Lack of Awareness Resulting in Patient Medication Errors
4.3.2 Stringent Regulatory Framework and Product Recalls
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Product Type
5.1.1 PCA Pumps
5.1.2 Pump Accessories
5.2 By Application
5.2.4 Other Applications
5.3 By End Users
5.3.2 Ambulatory Surgical Centers
5.3.3 Home-care Settings
5.4 By Geography
5.4.1 North America
22.214.171.124 United states
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.4.4 Middle East and Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle East and Africa
5.4.5 South America
126.96.36.199 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 ICU Medical Inc. (Smiths Medical)
6.1.3 BD (Becton, Dickinson and Company)
6.1.4 Fresenius SE & Co. KGaA
6.1.5 Micrel Medical Devices
6.1.6 Avante Health Solutions
6.1.7 B. Braun SE
6.1.8 Ace Medical
6.1.9 Terumo Corporation
6.1.11 Pfizer Inc. (Hospira)
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Patient-controlled Analgesia Pumps Market Research FAQs
What is the current Patient-controlled Analgesia Pumps Market size?
The Patient-controlled Analgesia Pumps Market is projected to register a CAGR of 5.20% during the forecast period (2024-2029)
Who are the key players in Patient-controlled Analgesia Pumps Market?
B. Braun SE, BD (Becton Dickinson, and Company), Baxter, Fresenius SE & Co. KGaA and ICU Medical, Inc (Smiths Medical) are the major companies operating in the Patient-controlled Analgesia Pumps Market.
Which is the fastest growing region in Patient-controlled Analgesia Pumps Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Patient-controlled Analgesia Pumps Market?
In 2024, the North America accounts for the largest market share in Patient-controlled Analgesia Pumps Market.
What years does this Patient-controlled Analgesia Pumps Market cover?
The report covers the Patient-controlled Analgesia Pumps Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Patient-controlled Analgesia Pumps Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Patient-controlled Analgesia Pumps Industry Report
Statistics for the 2024 Patient-controlled Analgesia Pumps market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Patient-controlled Analgesia Pumps analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.